Health TrialsbyHealthPanel

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

ConditionsMultiple MyelomaAmyloidosisCryoglobulinemiaCastleman's DiseaseLight Chain Deposition DiseaseHeavy Chain Deposition DiseasePolyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin ChangesSmoldering Multiple MyelomaPlasma Cell LeukemiaMonoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Renal Significance (MGRS)Monoclonal Gammopathy of Neurological Significance (MGNS)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University First Hospital

About this trial

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)

Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).

Patients are included into this cohort after signing the ICFs.

Disqualifiers

None

Trial population

Hospitalized patients with confirmed diagnosis of PCDs will be enrolled. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • No intervention

    Other intervention

    No intervention

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

To measure the treatment response in the cohort study of PCDs in PKUFH.The treatment response is done according to the criteria of the International Myeloma Working Group (IWMG) of 2016.

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University First Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now